Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML

Bone Marrow Transplantation volume 57, pages 384–390 (2022)Cite this article

Subjects

Abstract

The association of graft-versus-host disease (GVHD) and graft-versus-leukemia effect after stem-cell transplantation (SCT) is well established but with limited data in the setting of haploidentical SCT (haploSCT) with post-transplant cyclophosphamide (PTCy). We used a series of landmark analyses to investigate this association in 805 AML patients following haploSCT. On day +100, 707 patients were alive and leukemia-free, 500 had no prior acute GVHD, 137 had acute GVHD grade II and 70 had grade III–IV. Subsequent relapse rates were 20.3%, 23.2% and 15.0%, respectively (P = 0.52). Subsequent non-relapse mortality (NRM) was 8.6%, 17.8% and 38.6%, respectively (P < 0.0001). Leukemia-free survival (LFS) was 71.0%, 59.0% and 46.3%, respectively (P < 0.0001). Multivariate analysis showed that acute GVHD grade II and grade III–IV were not associated with relapse (HR 1.21, P = 0.37 and HR 1.03, P = 0.94), but were associated with increased NRM (HR 2.09, P = 0.005 and HR 6.41, P < 0.0001) and lower LFS (HR 1.47, P = 0.02 and HR 2.59, P = < 0.0001). Chronic GVHD was not associated with subsequent relapse. Extensive chronic GVHD was associated with higher NRM (HR 6.72, P < 0.0001) and inferior LFS (HR 3.29, P = < 0.0001). GVHD of any type or grade is not associated with lower relapse after haploSCT with PTCy. Severe forms are associated with higher NRM and lower survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Transplantation outcomes after haploidentical transplantation.
Fig. 2: Transplantation outcomes after haploidentical transplantation.

Similar content being viewed by others

References

  1. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720–8.

    Article  CAS  Google Scholar 

  2. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transpl Proc. 1981;13:(1 Pt 1) 248–51.

    CAS  Google Scholar 

  3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.

    Article  CAS  Google Scholar 

  4. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.

    Article  CAS  Google Scholar 

  5. Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia 2014;28:2235–40.

    Article  CAS  Google Scholar 

  6. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2017;52:191–6.

    Article  CAS  Google Scholar 

  7. Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–e584.

    Article  Google Scholar 

  8. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:132.

    Article  CAS  Google Scholar 

  9. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015;126:1033–40.

    Article  CAS  Google Scholar 

  10. Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1:477–85.

    Article  CAS  Google Scholar 

  11. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433–40.

    Article  CAS  Google Scholar 

  12. Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gülbas Z, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia 2019;33:230–9.

    Article  CAS  Google Scholar 

  13. McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, et al. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transpl. 2018;24:343–52.

    Article  CAS  Google Scholar 

  14. Mo XD, Xu LP, Zhang XH, Liu DH, Wang Y, Chen H, et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transpl. 2015;50:127–33.

    Article  Google Scholar 

  15. Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114–25.

    Article  CAS  Google Scholar 

  16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

    Article  CAS  Google Scholar 

  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos. 1958;53:457–81.

    Article  Google Scholar 

  19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

    Article  CAS  Google Scholar 

  20. Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34:70–85.

    Article  Google Scholar 

  21. Van Houwelingen HC, Putter H. Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data. Lifetime Data Anal. 2008;14:447–63.

    Article  Google Scholar 

  22. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074–8.

    Article  Google Scholar 

  23. Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357–73.

    Article  Google Scholar 

  24. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157.

    Article  Google Scholar 

  25. Pierini A, Ruggeri L, Mancusi A, Carotti A, Falzetti F, Terenzi A, et al. T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease. Bone Marrow Transpl. 2019;54:775–9. Suppl 2

    Article  CAS  Google Scholar 

  26. Ringdén O, Labopin M, Gorin NC, Schmitz N, Schaefer UW, Prentice HG, et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol. 2000;111:1130–7.

    PubMed  Google Scholar 

  27. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transpl. 2011;17:1343–51.

    Article  Google Scholar 

  28. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–50.

    Article  CAS  Google Scholar 

  29. McCurdy SR, Kanakry CG, Tsai HL, e Gojo I, Smith BD, Gladstone DE, et al. Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative hla-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide. Biol Blood Marrow Transpl. 2019;25:1128–35.

    Article  CAS  Google Scholar 

  30. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transpl. 2012;18:1727–33.

    Article  Google Scholar 

  31. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012;26:2462–8.

    Article  CAS  Google Scholar 

  32. Fleischhauer K, Beelen DW. HLA mismatching as a strategy to reduce relapse after alternative donor transplantation. Semin Hematol. 2016;53:57–64.

    Article  CAS  Google Scholar 

  33. Archbold JK, Macdonald WA, Burrows SR, Rossjohn J, McCluskey J. T-cell allorecognition: a case of mistaken identity or déjà vu? Trends Immunol. 2008;29:220–6.

    Article  CAS  Google Scholar 

  34. Brunstein CG, Petersdorf EW, DeFor TE, Noreen H, Maurer D, MacMillan M, et al. Impact of allele-level HLA mismatch on outcomes in recipients of double umbilical cord blood transplantation. Biol Blood Marrow Transpl. 2016;22:487–92.

    Article  Google Scholar 

  35. Ringdén O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia 2016;30:447–55.

    Article  Google Scholar 

  36. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–88.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the contribution of all the EBMT centers contributing patients to this study.

Author information

Authors and Affiliations

  1. Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Sackler Medical School Tel-Aviv University, Tel-Aviv, Israel

    Avichai Shimoni & Arnon Nagler

  2. Sorbonne University, INSERM UMRs 938, Paris, France

    Myriam Labopin, Mohamad Mohty & Arnon Nagler

  3. Ospedale San Martino, Department of Haematology II, Genova, Italy

    Emanuele Angelucci

  4. Programme de Transplantation&Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

    Didier Blaise

  5. Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute, Milan, Italy

    Fabio Ciceri

  6. Medicana International, Istanbul, Turkey

    Yener Koc

  7. Bone Marrow Transplantation Department,, Anadolu Medical Center Hospital, Kocaeli, Turkey

    Zafer Gülbas

  8. Hospital Gregorio Marañón, Sección de Trasplante de Medula Osea, Madrid, Spain

    J. L. Diez-Martin

  9. S.C.V.D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino, Torino, Italy

    Benedetto Bruno

  10. Department of Oncology and Haematology, Istituto Clinico Humanitas, Transplantation Unit, Milano, Italy

    Luca Castagna

  11. Grande Ospedale Metropolitano Bianchi Melacrino Morelli - Centro Unico Trapianti Alberto Neri, Reggio Calabria, Italy

    Massimo Martino

  12. Department of Hematology, Hospital Clinic, Institute of Hematology & Oncology, Barcelona, Spain

    Montserrat Rovira

  13. Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

    Mohamad Mohty

Authors
  1. Avichai Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myriam Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emanuele Angelucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabio Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yener Koc
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zafer Gülbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. L. Diez-Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Benedetto Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luca Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Massimo Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Montserrat Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS, ML, MM and AN, designed the research, analyzed and interpreted data, and wrote the manuscript; AS, ML, EA, DB, FC, YK, ZG, DMJL, BB, LC, MM, MR, MM and AN provided patients, collected and analyzed data, and critically reviewed the manuscript before submission. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Avichai Shimoni.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimoni, A., Labopin, M., Angelucci, E. et al. The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transplant 57, 384–390 (2022). https://doi.org/10.1038/s41409-021-01493-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01493-6

This article is cited by

Search

Advanced search

Quick links